Nyxoah SA

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Current securities

1. 6-K filingSep 22, 2026
2. 6-K filingJul 9, 2026
3. 6-K filingJun 23, 2026
4. 6-K filingJun 11, 2026
5. 6-K filingJun 8, 2026